Bristol-Myers Squibb, GeneCentric To Collaborate on Opdivo Biomarker Study | GenomeWeb

NEW YORK (GenomeWeb) – Bristol-Myers Squibb and GeneCentric Diagnostics are working together to explore whether GeneCentric's Cancer Subtype Platform can identify translational biomarkers for BMS's cancer immunotherapy Opdivo (nivolumab).

GeneCentric said it has also secured equity funding from BMS that will support the clinical development of its CSP and the build-out of its new laboratory in North Carolina's Research Triangle Park. It didn't disclose the amount of that investment, however.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.